BCR–ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention

References

• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–4022.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis - analysis of 242 patients. Am J Med 1987;83:445–454.
   PubMed Web of Science ®Google Scholar
• Pui L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 1994;13:764–773.
   PubMed Web of Science ®Google Scholar
• Griffin JD. Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother Pharmacol 2001;48:S11–S16.
   PubMed Web of Science ®Google Scholar
• Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134:171–179.
   PubMed Web of Science ®Google Scholar
• Ilaria RL, VanEtten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704–31710.
   PubMed Web of Science ®Google Scholar
• Shuai K, Halpern J, tenHoeve J, Rao XP, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247–254.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson CHM, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254–2264.
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008;68:2576–2580.
   PubMed Web of Science ®Google Scholar
• Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991;88:6293–6297.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Shi JY, Li JY. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res 2009;33:1141–1143.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of IKAROS. Nature 2008;453:110–114.
   PubMed Web of Science ®Google Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008;68:6884–6888.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schafer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000;79:424–431.
   PubMed Web of Science ®Google Scholar
• Gaiger A, Henn T, Horth E, et al. Increase of Bcr-Abl chimeric messenger-RNA expression in tumor-cells of patients with chronic myeloid-leukemia precedes disease progression. Blood 1995;86:2371–2378.
   PubMed Web of Science ®Google Scholar
• Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355–368.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2. Nat Genet 2002;30:48–58.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34(+) cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893–4894.
   PubMed Web of Science ®Google Scholar
• Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 rnRNA translation via the La antigen. Cancer Cell 2003;3:145–160.
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska M, Koptyra M, Hoser G, et al. Mechanisms generating free radicals in CML stem/progenitor cell populations causing DNA damage and genomic instability. Blood 2008;112:78–79.
   Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965–1971.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 2007;204:461–465.
   PubMed Web of Science ®Google Scholar
• Laudadio J, Deininger MWN, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn 2008;10:177–180.
   PubMed Web of Science ®Google Scholar
• Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35–43.
   PubMed Web of Science ®Google Scholar
• Klein F, Feldhahn N, Herzog S, et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006;25:1118–1124.
   PubMed Web of Science ®Google Scholar
• Salesse S, Dylla SJ, Verfaillie C. p210(BCR/ABL)-induced alteration of pre-mRNA splicing in primary human CD34(+) hematopoietic progenitor cells. Leukemia 2004;18:727–733.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Munthe HA, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired beta 1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol 1999;27:1384–1396.
   PubMed Web of Science ®Google Scholar
• Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 1997;100:46–57.
   PubMed Web of Science ®Google Scholar
• Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996;87:3883–3891.
   PubMed Web of Science ®Google Scholar
• Verfaillie CM, McCarthy JB, McGlave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 1991;174:693–703.
   PubMed Web of Science ®Google Scholar
• Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009;106:3925–3929.
   PubMed Web of Science ®Google Scholar
• Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528–541.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047–2053.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL(+) leukemia cells. J Clin Invest 2008;118:3038–3050.
   PubMed Web of Science ®Google Scholar
• Ren SY, Xue F, Feng J, Skorski T. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol–3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Exp Hematol 2005;33:1222–1228.
   PubMed Web of Science ®Google Scholar
• Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716–5722.
   PubMed Web of Science ®Google Scholar
• Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130–3135.
   PubMed Web of Science ®Google Scholar
• Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFN alpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005;106:2436–2443.
   PubMed Web of Science ®Google Scholar
• Markova B, Albers C, Breitenbuecher F, et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma 1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 2010;29:739–751.
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457–468.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001;15:2852–2864.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–1945.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596–603.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913–963.
   PubMed Web of Science ®Google Scholar
• Lim S, Saw TY, Chuah C, Ong ST. Overexpression and phosphorylation of eIF4E is required for beta-catenin activation in blast crisis chronic myelogenous leukemia. Blood 2009;114:22.
   Web of Science ®Google Scholar
• Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 2007;26:1188–1200.
   PubMed Web of Science ®Google Scholar
• Janes MR, Limon JJ, So LM, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205–213.
   PubMed Web of Science ®Google Scholar
• Zhang M, Fu WX, Prabhu S, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008;28:6496–6509.
   PubMed Web of Science ®Google Scholar
• Altman JK, Yoon P, Katsoulidis E, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 2008;283:1992–2001.
   Google Scholar
• Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767–3775.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427–1434.
   PubMed Web of Science ®Google Scholar
• Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3–12.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8:931–937.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886–897.
   PubMed Web of Science ®Google Scholar
• Baehrecke EH. Autophagy: DUAL roles in life and death? Nat Rev Mol Cell Biol 2005;6:505–510.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726–734.
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741–752.
   PubMed Web of Science ®Google Scholar
• Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120:237–248.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
   PubMed Web of Science ®Google Scholar
• Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3:195–205.
   PubMed Web of Science ®Google Scholar
• Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci USA 2001;98:7018–7024.
   PubMed Web of Science ®Google Scholar
• Keene JD, Tenenbaum SA. Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell 2002;9:1161–1167.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002;21:8577–8583.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Turturro F, Neviani P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ 2005;12:534–540.
   PubMed Web of Science ®Google Scholar
• Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006;107:2507–2516.
   Google Scholar
• Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J 1998;17:4442–4455.
   PubMed Web of Science ®Google Scholar
• Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 2002;22:2255–2266.
   PubMed Web of Science ®Google Scholar
• Guerzoni C, Bardini M, Mariani SA, et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BICRABL-expressing cells. Blood 2006;107:4080–4089.
   PubMed Web of Science ®Google Scholar
• Dreyfuss G, Matunis MJ, Pinolroma S, Burd CG. Hnrnp proteins and the biogenesis of messenger-RNA. Annu Rev Biochem 1993;62:289–321.
   PubMed Web of Science ®Google Scholar
• Guil S, Caceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol 2007;14:591–596.
   PubMed Web of Science ®Google Scholar
• Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34(+) cells. Blood 2007;109:4399–4405.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Neviani P, Santhanam R, et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008;111:816–828.
   Google Scholar
• Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408–2421.
   PubMed Web of Science ®Google Scholar
• Vera J, Jaumot M, Estanyol JM, Brun S, Agell N, Bachs O. Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. Oncogene 2006;25:260–270.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007;13:1638–1642.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Callahan W, Witte ON. Dominant negative Myc blocks transformation by Abl oncogenes. Cell 1992;70:901–910.
   PubMed Web of Science ®Google Scholar
• Evans JR, Mitchell SA, Spriggs KA, et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 2003;22:8012–8020.
   PubMed Web of Science ®Google Scholar
• Michelotti EF, Michelotti GA, Aronsohn AI, Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 1996;16:2350–2360.
   PubMed Web of Science ®Google Scholar
• Gopal V, Kadam P, Preisler H, et al. Abnormal regulation of the Myc gene in myeloid-leukemia. Med Oncol Tumor Pharmacother 1992;9:139–147.
   PubMedGoogle Scholar
• Park YG, Zhao XH, Lesueur F, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005;37:1055–1062.
   PubMed Web of Science ®Google Scholar
• Naarmann IS, Harnisch C, Flach N, et al. mRNA silencing in human erythroid cell maturation - heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src. J Biol Chem 2008;283:18461–18472.
   PubMed Web of Science ®Google Scholar
• Wolin SL, Cedervall T. The LA protein. Annu Rev Biochem 2002;71:375–403.
   PubMed Web of Science ®Google Scholar
• Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000;95:1144–1150.
   PubMed Web of Science ®Google Scholar
• Skorski T, NieborowskaSkorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p210(bcr/abl) tyrosine kinase. Proc Natl Acad Sci USA 1996;93:13137–13142.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Mayerhofer M, Florian S, et al. BCR/ABL-dependent expression of Mcl-1 involves the MAP-kinase pathway and contributes to survival of leukemic cells. Blood 2003;102(Suppl. 1): Abstract 4987.
   Google Scholar
• Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005;105:3303–3311.
   PubMed Web of Science ®Google Scholar
• Fukuchi Y, Kizaki H, Yamato K, et al. Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells. Oncogene 2001;20:704–713.
   PubMed Web of Science ®Google Scholar
• Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBP alpha is required for induction of granulocytic differentiation. Blood 2003;102:1267–1275.
   PubMed Web of Science ®Google Scholar
• Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89–101.
   PubMed Web of Science ®Google Scholar
• Ostareck-Lederer A, Ostareck DH. Control of mRNA translation and stability in haematopoietic cells: The function of hnRNPs K and E1/E2. Biol Cell 2004;96:407–411.
   PubMed Web of Science ®Google Scholar
• Chang JS, Santhanam R, Trotta R, et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007;110:994–1003.
   PubMed Web of Science ®Google Scholar
• Wagner K, Zhang P, Rosenbauer F, et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA 2006;103:6338–6343.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. J Clin Oncol 2004;22:582–584.
   PubMed Web of Science ®Google Scholar
• Waggoner SA, Johannes GJ, Liebhaber SA. Depletion of the poly(C)-binding proteins alpha CP1 and alpha CP2 from K562 cells leads to p53-independent induction of cyclin-dependent kinase inhibitor (CDKN1A) and G1 arrest. J Biol Chem 2009;284:9039–9049.
   PubMed Web of Science ®Google Scholar
• Jones LC, Lin ML, Chen SS, et al. Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. Blood 2002;99:2032–2036.
   PubMed Web of Science ®Google Scholar
• Timchenko NA, Welm AL, Lu XH, Timchenko LT. CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBP beta mRNA and regulates translation of C/EBP beta isoforms. Nucleic Acids Res 1999;27:4517–4525.
   PubMed Web of Science ®Google Scholar
• Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci 1997;110:1741–1750.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Iervolino A, Cesi V, et al. BCR-ABL prevents c-Jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase C beta II-dependent pathway. Mol Cell Biol 2000;20:6159–6169.
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature 2004;431:350–355.
   PubMed Web of Science ®Google Scholar
• Bueno MJ, de Castro IP, de Cedron MG, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008;13:496–506.
   PubMed Web of Science ®Google Scholar
• Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787–798.
   PubMed Web of Science ®Google Scholar
• O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839–843.
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257–2261.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834–838.
   PubMed Web of Science ®Google Scholar
• Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat Genet 2004;36:257–263.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010;140:652–665.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005;105:324–334.
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E, Roman-Gomez J, Jimenez-Velasco A, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer 2009;8:69.
   PubMed Web of Science ®Google Scholar
• Agirre X, Jimenez-Velasco A, Jose-Eneriz ES, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34(+) cells increases USF2-mediated cell growth. Mol Cancer Res 2008;6:1830–1840.
   PubMed Web of Science ®Google Scholar
• Heo I, Joo C, Cho J, Ha M, Han JJ, Kim VN. Lin28 mediates the terminal uridylation of Let-7 precursor microRNA. Mol Cell 2008;32:276–284.
   PubMed Web of Science ®Google Scholar
• Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008;14:1539–1549.
   PubMed Web of Science ®Google Scholar
• Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008;10:987–993.
   PubMed Web of Science ®Google Scholar
• Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of MicroRNA processing by Lin28. Science 2008;320:97–100.
   PubMed Web of Science ®Google Scholar
• Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009;41:843–848.
   PubMed Web of Science ®Google Scholar
• Schotte D, Chau JCK, Sylvester G, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 2009;23:313–322.
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762–9770.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635–647.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. US food and drug administration drug approval summary: conversion of imatinib mesylate (ST1571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12–19.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006;95:775–781.
   Google Scholar
• Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010;95:1325–1333.
   PubMed Web of Science ®Google Scholar